Vaccine candidate

Danish biotech MinervaX has launched the first Phase I clinical study in older adults of its novel Group B Streptococcus (GBS) vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. GBS is a global unmet medical burden and can cause serious illness in people of all ages, worldwide. It is normally associated with infection in […]

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s vaccine candidate Qdenga for active immunisation against dengue infection from four years of age.  Dengue is the fastest spreading mosquito-borne virus and was recognised by the World Health Organization (WHO) in 2019 as one of the top ten threats to […]

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.   SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease. The new vaccine, VSV-SUDV, completely protected cynomolgus macaques against a lethal SUDV challenge. […]

An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial.  In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of time would be a crucial part of quelling […]

New research from the International Longevity Centre (ILC) in London, UK, finds that social media advertising can be a cost-effective way of engaging older people in deprived communities with vaccination.  The approach  In the past, researchers found that older people are less likely to use social media than younger generations. As evidence suggests that younger […]

Levels of antibodies in the blood of vaccinated people that can recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) […]

Novavax has announced its participation in a newly expanded investigator-initiated Phase II clinical trial called Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. Novavax’ recombinant protein vaccine candidate, NVX-CoV2373, is one of four Covid-19 vaccines that will be studied […]

RSV is a complicated virus, and traditional vaccine methods have not worked. But UW’s Institute for Protein Design may have solved the problem using computational design. With the help of an innovative computer program, Icosavax has constructed virus-like particles (VLPs) using a two-part assembly (like a soccer ball). Adam Simpson, CEO of Icosavax, talks to […]